Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Rasagiline mesylate - Generic Drug Details

« Back to Dashboard
Rasagiline mesylate is the generic ingredient in two branded drugs marketed by Watson Labs Inc, Teva, Apotex Inc, and Orchid Hlthcare, and is included in four NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and eleven patent family members in thirty-four countries.

There are seventeen drug master file entries for rasagiline mesylate. Three suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: rasagiline mesylate

Tradenames:2
Patents:4
Applicants:4
NDAs:4
Drug Master File Entries: see list17
Suppliers / Packaging: see list3
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: rasagiline mesylate

Tentative approvals for RASAGILINE MESYLATE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET;ORAL0.5MG
<disabled><disabled>TABLET;ORAL1MG
<disabled><disabled>TABLET;ORALEQ 0.5MG BASE

Clinical Trials for: rasagiline mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc
RASAGILINE MESYLATE
rasagiline mesylate
TABLET;ORAL201950-001Sep 12, 2013RXNo<disabled><disabled>
Apotex Inc
RASAGILINE MESYLATE
rasagiline mesylate
TABLET;ORAL201950-002Sep 12, 2013RXNo<disabled><disabled>
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006RXYes7,572,834<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: rasagiline mesylate

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-001May 16, 20065,457,133<disabled>
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-002May 16, 20065,387,612<disabled>
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-001May 16, 20065,532,415<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: rasagiline mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,891,923 R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia<disabled in preview>
5,519,061 R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof<disabled in preview>
5,576,353 Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: rasagiline mesylate

Country Document Number Estimated Expiration
Canada2600011<disabled in preview>
Russian Federation2404746<disabled in preview>
South Korea20070111534<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RASAGILINE MESYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00205Netherlands<disabled>PRODUCT NAME: RASAGILINE, DESGEWENST IN DE VORM VAN EENFARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/04/304/001 T/M 007 20050221
2005 00039Denmark<disabled>
/2005Austria<disabled>PRODUCT NAME: RASAGILINE; REGISTRATION NO/DATE: EU/1/04/304/001-007 20050221
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc